Blueprint Medicines Competitors and Similar CompaniesClear all
Blueprint Medicines's competitors and similar companies include Halozyme Therapeutics, Deciphera Pharmaceuticals, Repare Therapeutics and Ohm Oncology.
 Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells. |  Ohm Oncology Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds. | |
Founding Date | Founding Date 2011 | Founding Date 1998 | Founding Date 2003 | Founding Date 2016 | Founding Date 2015 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations San Diego, US HQ | Locations Waltham, US HQ Lawrence, US | Locations Montréal, CA HQ Cambridge, US | Locations Austin, US HQ |
Employees | Employees 6552% increase | Employees 373157% increase | Employees 35037% increase | Employees 179 | Employees 167% decrease |
Valuation ($) | Valuation ($) 5.3 b | Valuation ($) 6.4 b | Valuation ($) 2.2 b | Valuation ($) 152.4 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $249.4m (FY, 2023) | Revenue (est.) $829.3m (FY, 2023) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) $51.1m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods $8.5m (FY, 2023) | Cost of goods $192.4m (FY, 2023) | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $240.8m (FY, 2023) | Gross profit $636.9m (FY, 2023) | Gross profit $159.6m (FY, 2023) | Gross profit $51.1m (FY, 2023) | Gross profit N/A |
Net income | Net income ($507m) (FY, 2023) | Net income $281.6m (FY, 2023) | Net income ($194.9m) (FY, 2023) | Net income ($93.8m) (FY, 2023) | Net income N/A |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications 50 (FY, 2020) | Patent Applications 49 (Aug, 2017) | Patent Applications N/A | Patent Applications N/A |
Patents (US) | Patents (US) N/A | Patents (US) 43 (FY, 2020) | Patents (US) 11 (Aug, 2017) | Patents (US) N/A | Patents (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 1.7b | Total funding raised $ 171.9m | Total funding raised $ 714m | Total funding raised $ 150.5m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Halozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyDeciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View companyRepare Therapeutics
HQ
Montréal, CA
Employees
179
Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.
View companyOhm Oncology
HQ
Austin, US
Employees
1
Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds.
View company